JPRN-UMIN000002691
Completed
未知
Phase II trial of combination chemotherapy consisting of pegylated liposomal doxorubicin and carboplatin in patients with recurrent ovarian cancer - Phase II trial of PLD-carboplatin in recurrent ovarian cancer patients
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Epithelial ovarian cancer, primary fallopian tube cancer, or peritoneal cancer in late relapse (>
- Sponsor
- Keio University, School of Medicine
- Enrollment
- 33
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients with severe complications or active infection. 2\. Patients with prior diagnosis of malignancy are not eligible. Exceptions are: \-non\-melanoma skin cancer, and carcinoma in situ. \-other malignancies curatively treated and \> 5 years without evidence of recurrence. 3\. Patients with massive pleural effusion and/or ascites. 4\. Patients with massive pericardial fluid. 5\. Patients with unstable angina or those who have had a myocardial infarction within the past 90 days. 6\. Patients with brain metastasis who have symptoms or require administration of steroid or antihydropic. 7\. Patients who have received prior bone marrow transplantation, or high\-dose chemotherapy and hematopoietic stem cell transplantation. 8\. Patients who have received prior chemotherapy consisting of pegylated liposomal doxorubicin. 9\. Patients who have participated in other clinical trials. 10\. Patients who have received prior chemotherapy consisting of doxorubicin. 11\. Patients with history of hypersensitivity reactions to the components of pegylated liposomal doxorubicin. 12\. Patients who are pregnant, lactating, and have pregnant possibility or intention. 13\. Patients who are decided to be ineligible for this trial by the investigators.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase II trial of combination chemotherapy consisting of S-1 and Oxaliplatin in patients with advanced or recurrent mucinous adenocarcinoma of the ovaryMucinous adenocarcinoma of the ovary including metastatic ovarian cancerJPRN-UMIN000001541Japan ovarian mucinous adenocarcinoma study group40
Completed
Phase 2
Phase II clinical trial of combination chemotherapy with bendamustine and rituximab for relapsed or refractory CD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma patientsCD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaJPRN-UMIN000008024Kyoto University Hematology Study Group45
Active, not recruiting
Not Applicable
Klinisk prövning med kombinationsbehandling av kemoterapi och antikroppar för behandling av patienter med gallgångscancer som inte kan opereras.EUCTR2010-020385-13-SEVejle Hospital78
Active, not recruiting
Phase 1
Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutations - GOC-B-PEUCTR2010-020385-13-DKVejle Hospital
Recruiting
Phase 1
Phase I/II trial of combination chemotherapy using TS-1, CPT-11 and cetuximab with radiation in locally advanced rectal cancerRectal cancerJPRN-UMIN000002602Yokohama City University Graduate School of Medicine35